Loading provider…
Loading provider…
Ophthalmology Physician in Pasadena, CA
NPI: 1740485895Primary Practice Location
Pasadena Eye Medical Group
10 Congress St, Pasadena, CA
Primary Employer
Pasadena Eye Medical Group
pasadenaeyemed.com
HQ Phone
Get M.D. Vicky's Phone Numberphone_androidMobile
Get M.D. Vicky's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2008 - 2026

American Board of Ophthalmology
Ophthalmology
UCLA David Geffen School of Medicine/UCLA Medical Center/UCLA Stein and Doheny Eye Institutes
Residency • Ophthalmology
2008 - 2011
Olive View/UCLA Medical Center
Internship • Internal Medicine
2007 - 2008
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 2007
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 92014Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | 409 | 432 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 293 | 442 |
| 3 | 92133Diagnostic imaging of optic nerve of eye | 150 | 173 |
| 4 | 92004Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | 118 | 118 |
| 5 | 92250Photography of the retina | 112 | 114 |
MUC16 as a sensitive and specific marker for epithelial downgrowth.
Authors: Vicky Pai, Ben Glasgow
Publication Date: 2010-11-10
Authors: Lynn Gordon, Ralph Levinson
Journal: Ocul Immunol Inflamm
MUC16 as a Sensitive and Specific Marker for Epithelial Downgrowth
Authors: Pai, Vicky C, Glasgow, Ben J
Journal: Arch Ophthalmol
Lead Sponsor: Senju Pharmaceutical Co., Ltd.
Intervention / Treatment: DRUG: Vehicle of SJP-0035 Ophthalmic Solution, DRUG: SJP-0035 Ophthalmic Solution
Lead Sponsor: Shire
Intervention / Treatment: DRUG: Placebo, DRUG: PVP-I 0.6%, DRUG: SHP640
Lead Sponsor: Shire
Intervention / Treatment: OTHER: Placebo, DRUG: PVP-I 0.6%, DRUG: SHP640